Clearside Biomedical, Inc. (CLSDQ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Clearside Biomedical, Inc. (CLSDQ) trades at $0.249 with AI Score 50/100 (Grade B). Clearside Biomedical, Inc. is a biopharmaceutical company specializing in therapies for eye diseases, particularly those affecting the back of the eye. Market cap: $1.30M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for CLSDQ: CLSDQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CLSDQ against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CLSDQ: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Clearside Biomedical, Inc. (CLSDQ) Healthcare & Pipeline Overview
Clearside Biomedical, Inc. focuses on revolutionizing therapies for the back of the eye through its suprachoroidal space delivery platform, featuring XIPERE for macular edema and CLS-AX for wet AMD. Despite innovative approaches and strategic collaborations, the company filed for Chapter 11 reorganization in late 2025.
What Is the Investment Thesis for CLSDQ?
Clearside Biomedical's innovative suprachoroidal space (SCS) delivery platform offers a novel approach to treating retinal diseases. XIPERE's approval for macular edema associated with uveitis demonstrates the platform's potential. The company's pipeline, including CLS-AX for wet AMD, represents further growth opportunities. However, the company's Chapter 11 filing on November 23, 2025, introduces substantial risk. The company's negative profit margin of -780.9% and current market capitalization of $1.30M highlight its financial instability. Investors should carefully consider the implications of the bankruptcy proceedings and the company's ability to restructure and regain financial health before making any investment decisions. The high beta of 1.87 suggests significant volatility.
Based on FMP financials and quantitative analysis
CLSDQ Key Highlights
XIPERE is approved for the treatment of macular edema associated with uveitis, showcasing the potential of Clearside's SCS delivery platform.
- CLS-AX, an axitinib injectable suspension, completed Phase 2 clinical trials for wet AMD, indicating pipeline progress.
- Gross margin of 85.6% suggests strong pricing power for XIPERE.
- The company filed for Chapter 11 reorganization on November 23, 2025, due to financial difficulties.
- Market Cap is $0.00B, reflecting the company's distressed financial state.
Who Are CLSDQ's Competitors?
CLSDQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CDTX Cidara Therapeutics, Inc. | $221.38 | +0.00% | $5.61B | 46 |
| CGEM Cullinan Therapeutics, Inc. | $22.52 | +8.06% | $1.38B | 57 |
| CNTB Connect Biopharma Holdings Limited | $2.28 | -7.32% | $144M | — |
| CRVS Corvus Pharmaceuticals, Inc. | $14.33 | -6.95% | $1.21B | 59 |
| CYPH Cypherpunk Technologies Inc. | $1.19 | +11.21% | $127M | 41 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CLSDQ's Key Strengths?
Innovative suprachoroidal space (SCS) delivery platform.
- Approved product (XIPERE) for macular edema associated with uveitis.
- Strategic collaborations with established pharmaceutical companies.
- Patent protection for its technology and products.
What Are CLSDQ's Weaknesses?
Chapter 11 bankruptcy filing.
- Negative profit margin.
- Limited product portfolio.
- Dependence on strategic collaborations.
What Could Drive CLSDQ Stock Higher?
Potential emergence from Chapter 11 reorganization.
- Continued sales and marketing of XIPERE.
- Progress in strategic collaborations with partners.
What Are the Key Risks for CLSDQ?
Financial-distress signal — its Altman Z-Score of -48.28 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Chapter 11 bankruptcy proceedings and potential liquidation.
- Failure to secure funding for continued operations and clinical development.
- Competition from other companies developing therapies for retinal diseases.
- Regulatory setbacks and delays in clinical trials.
- Limited liquidity and trading volume on the OTC market.
What Are the Growth Opportunities for CLSDQ?
- Expansion of XIPERE's Label: Clearside has the opportunity to expand the label for XIPERE to include other indications beyond macular edema associated with uveitis. This could significantly increase the addressable market for the drug. The timeline for this expansion depends on the results of further clinical trials and regulatory approvals, potentially within the next 3-5 years. Success here hinges on demonstrating XIPERE's efficacy and safety in treating other retinal diseases.
- Advancement of CLS-AX for Wet AMD: The successful development and commercialization of CLS-AX for wet AMD represents a significant growth opportunity. Wet AMD is a major cause of vision loss, and a new treatment option could capture a substantial market share. The timeline for this depends on the company's ability to emerge from bankruptcy and fund further clinical trials, with potential commercialization in 5-7 years.
- Strategic Partnerships: Clearside can leverage its existing collaborations with companies like Bausch + Lomb and REGENXBIO to develop and commercialize new therapies using its SCS delivery platform. These partnerships can provide funding, expertise, and access to new markets. The success of these partnerships depends on the partners' commitment and the successful development of new products, with potential impact within the next 2-4 years.
- New Product Development: Clearside can continue to develop new products utilizing its SCS delivery platform to target other eye diseases. This requires ongoing investment in research and development, but it could lead to the discovery of new therapies and further growth opportunities. The timeline for this is long-term, with potential impact in 5-10 years.
- Geographic Expansion: Clearside can expand its geographic reach by commercializing XIPERE and other products in new markets outside the United States. This requires regulatory approvals and the establishment of distribution networks. The timeline for this expansion depends on the company's ability to secure funding and navigate regulatory hurdles, with potential impact within the next 3-5 years.
What Threats Does CLSDQ Face?
- Competition from other companies developing therapies for retinal diseases.
- Regulatory hurdles and lengthy clinical trial processes.
- Patent expiration and generic competition.
- Financial instability and the risk of liquidation.
What Are CLSDQ's Competitive Advantages?
- Proprietary Suprachoroidal Space (SCS) Delivery Platform: This platform allows for targeted drug delivery to the back of the eye, an area difficult to reach with conventional methods.
- Approved Product: XIPERE is an approved product for macular edema associated with uveitis, providing a revenue stream and validation of the SCS platform.
- Strategic Collaborations: Partnerships with established pharmaceutical companies provide access to funding, expertise, and new markets.
- Patent Protection: Clearside has patents protecting its SCS delivery platform and products.
What Does CLSDQ Do?
Clearside Biomedical, Inc., incorporated in 2011 and headquartered in Alpharetta, Georgia, is a biopharmaceutical company dedicated to developing and delivering innovative therapies for sight-threatening diseases. The company specializes in accessing the suprachoroidal space (SCS) to deliver treatments to the back of the eye, an area traditionally difficult to reach with conventional methods. Clearside's lead product, XIPERE, is a triamcinolone acetonide injectable suspension approved for the treatment of macular edema associated with uveitis. In addition to XIPERE, Clearside has been developing CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trials for the treatment of wet age-related macular degeneration (AMD). Clearside has established collaborations with several pharmaceutical companies, including Bausch + Lomb Ireland Limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc., to expand the application of its SCS delivery platform. However, on November 23, 2025, Clearside Biomedical filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware, indicating significant financial challenges despite its innovative technology and partnerships.
What Products and Services Does CLSDQ Offer?
- Develops therapies for eye diseases, focusing on the back of the eye.
- Utilizes the suprachoroidal space (SCS) for targeted drug delivery.
- Offers XIPERE for the treatment of macular edema associated with uveitis.
- Develops CLS-AX for the treatment of wet AMD.
- Collaborates with pharmaceutical companies to expand its SCS delivery platform.
- Seeks to revolutionize the treatment of sight-threatening diseases.
How Does CLSDQ Make Money?
- Develops and commercializes ophthalmic therapies.
- Generates revenue through sales of XIPERE.
- Forms strategic collaborations to develop and commercialize new products.
- Out-licenses its SCS delivery platform to other companies.
What Industry Does CLSDQ Operate In?
Clearside Biomedical operates within the biotechnology industry, specifically targeting the ophthalmology market. This market is characterized by increasing prevalence of eye diseases such as macular edema and wet AMD, driving demand for innovative therapies. Competition includes companies developing novel drug delivery systems and therapeutic agents for retinal diseases. The industry is subject to stringent regulatory requirements and lengthy clinical trial processes. Clearside's suprachoroidal space delivery platform aims to differentiate itself by offering targeted drug delivery to the back of the eye.
Who Are CLSDQ's Key Customers?
- Patients with macular edema associated with uveitis.
- Patients with wet age-related macular degeneration (AMD).
- Ophthalmologists and retinal specialists.
- Pharmaceutical companies seeking innovative drug delivery technologies.
Clearside Biomedical, Inc. Financial Trajectory
Clearside Biomedical, Inc. (CLSDQ) reported $201K in revenue for Q3 2025, a decline of 59.1% compared to the prior quarter. The company recorded a net loss of $6.0M, with diluted EPS of $-1.14. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, CLSDQ averaged $-1.26 in diluted EPS.
Company Profile
Clearside Biomedical, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Alpharetta, US. The company is led by CEO George Lasezkay. CLSDQ has traded publicly since 2016.
How Clearside Biomedical, Inc. Is Valued
Clearside Biomedical, Inc. carries a market capitalization of $1.30M, placing it in the micro-cap category. Relative to its peer group, CLSDQ's quantitative score of 50/100 is roughly in line with the peer average of 51/100.
Key Financial Metrics
Return on equity for Clearside Biomedical, Inc. stands at 37.7%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 2.98 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Clearside Biomedical, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -48.28 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Clearside Biomedical, Inc. has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 647.9% below estimates on average.
Forward Outlook
Wall Street analysts project Clearside Biomedical, Inc. revenue of about $1.5M for fiscal 2026, with EPS near $-3.30.
CLSDQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future and potential recovery.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative treatment options.
- Recent partnerships and collaborations have sparked interest, indicating a strategic direction that could enhance growth.
- Market perception is improving as the company gains visibility in the biotech sector, attracting attention from investors.
Bear Case
- Concerns remain about the company's financial health following previous losses, leading to skepticism among some investors.
- Recent social sentiment has shown mixed reactions, with some community members expressing doubts about the sustainability of its business model.
- Ongoing regulatory challenges in the biotech space can create uncertainty, impacting investor confidence.
- Market volatility in the sector may overshadow Clearside's potential, leading to cautious sentiment among traders.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $201,000 | -$6M | -$1.14 |
| Q2 2025 | $492,000 | -$4M | -$0.87 |
| Q1 2025 | $2M | -$8M | -$1.60 |
| Q4 2024 | $306,000 | -$7M | -$1.44 |
Based on FMP financials and quantitative analysis
CLSDQ Latest News
No recent news available for CLSDQ.
CLSDQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CLSDQ.
Price Targets
Wall Street price target analysis for CLSDQ.
CLSDQ MoonshotScore
What does this score mean?
The MoonshotScore rates CLSDQ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: George Lasezkay
CEO
George Lasezkay serves as the CEO of Clearside Biomedical, Inc. His background includes experience in the pharmaceutical and biotechnology industries. Information regarding his specific career history, education, and previous roles is not available in the provided data.
Track Record: Due to the limited information available, it is difficult to assess George Lasezkay's track record at Clearside Biomedical. The company's Chapter 11 filing occurred under his leadership. Further information is needed to evaluate his strategic decisions and contributions to the company's milestones.
CLSDQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Clearside Biomedical does not meet the minimum financial standards or reporting requirements for the higher tiers (OTCQX and OTCQB). Companies in this tier may be distressed, have limited operating history, or be unwilling or unable to provide audited financial statements. Investing in OTC Other stocks carries significant risks compared to stocks listed on major exchanges like the NYSE or NASDAQ, which have stricter listing requirements and greater regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low liquidity and wide bid-ask spreads.
- Higher risk of fraud or manipulation.
- Potential for delisting or going out of business.
- Limited regulatory oversight.
- Verify the company's legal status and registration.
- Review available financial information, even if unaudited.
- Assess the company's management team and their experience.
- Understand the company's business model and competitive landscape.
- Evaluate the company's debt and cash flow situation.
- Consider the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before investing.
- Established collaborations with reputable pharmaceutical companies.
- FDA approval for XIPERE.
- Completion of Phase 2 clinical trials for CLS-AX.
- History of operations since 2011.
- Presence of a CEO and management team.
What Investors Ask About Clearside Biomedical, Inc. (CLSDQ) — Healthcare
What does the AI Score mean for CLSDQ?
CLSDQ holds an AI Score of 50/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Clearside Biomedical, Inc. is a biopharmaceutical company specializing in therapies for eye diseases, particularly those affecting the back of the eye. The company filed for Chapter 11 …
What does Clearside Biomedical, Inc. do?
Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for eye diseases, particularly those affecting the back of the eye. The company's proprietary suprachoroidal space (SCS) delivery platform allows for targeted drug delivery to the retina and other posterior structures of the eye.
What do analysts say about CLSDQ stock?
Due to the company's Chapter 11 filing and its trading status on the OTC Other tier, analyst coverage is likely limited. Key valuation metrics such as P/E ratio (-0.11) and market capitalization ($0.00B) reflect the company's distressed financial situation. Growth considerations depend on the company's ability to restructure its debt, secure additional funding, and continue developing its pipeline.
What are the main risks for CLSDQ?
The main risks for Clearside Biomedical include the ongoing Chapter 11 bankruptcy proceedings, which could result in liquidation or significant dilution for existing shareholders. The company's limited financial resources and negative profit margin (-780.9%) pose challenges to its ability to fund continued operations and clinical development. Competition from other companies developing therapies for retinal diseases also presents a risk.
What are the key factors to evaluate for CLSDQ?
Clearside Biomedical, Inc. (CLSDQ) holds an AI score of 50/100 (moderate). Clearside Biomedical's innovative suprachoroidal space (SCS) delivery platform offers a novel approach to treating retinal diseases. Not financial advice.
How frequently does CLSDQ data refresh on this page?
CLSDQ's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CLSDQ's recent stock price performance?
Clearside Biomedical, Inc. (CLSDQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative suprachoroidal space (SCS) delivery platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CLSDQ overvalued or undervalued right now?
Clearside Biomedical, Inc. (CLSDQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CLSDQ before investing?
Before investing in Clearside Biomedical, Inc. (CLSDQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- The company's financial situation is subject to change due to the Chapter 11 bankruptcy proceedings.
- Analyst opinions may be limited due to the company's OTC trading status.